netFormulary Berkshire West NHS NHS
Royal Berkshire NHS Foundation Trust
Berkshire Healthcare NHS Foundation Trust
Berkshire West Clinical Commissioning Group
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:
This formulary is used by multiple organisations. There may be some instances where an item is on the formulary for one organisation but not the others. To help distinguish between each organisation, text will be colour coded, i.e. information relating to the Royal Berkshire NHS Foundation Trust will be in blue and Berkshire Healthcare NHS Foundation Trust will be in purple. Please ensure you read all information detailed under a drug.   
Chapter Links...
 Details...
08.03.04.01  Expand sub section  Breast cancer
Anastrozole
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
Please do not prescribe by brand

Royal Berkshire NHS Foundation Trust >> Formulary Item tablets
 
   
Exemestane
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Amber
Not first line

Royal Berkshire NHS Foundation Trust >> Formulary Item tablets - for specialist use ONLY
 
Link  NICE TA 421 - Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
   
Goserelin-Zoladex
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
Royal Berkshire NHS Foundation Trust >> Formulary Item injection (3.6mg implant only)
 
   
Letrozole
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Amber
Royal Berkshire NHS Foundation Trust >> Formulary Item tablets - specialist use ONLY
 
   
Tamoxifen
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
Royal Berkshire NHS Foundation Trust >> Formulary Item tablets / oral solution
 
Link  Drug interactions, genetic variants and variability in clinical response (MHRA drug safety update Nov 2010)
   
 ....
 Non Formulary Items
Fulvestrant  (Faslodex)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Red
Royal Berkshire NHS Foundation Trust>> NON - Formulary Item - contact pharmacy for advice
Link  East Midlands Cancer Network : Hormone Algorithm - Advanced Breast Cancer
Link  NICE TA 503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
Link  NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
 
Tamoxifen  (Nolvadex-D)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Amber
Royal Berkshire NHS Foundation Trust>> NON - Formulary Item see generic drug for details (brand may not be available - contact pharmacy for advise)
 
Toremifene  (Fareston)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Amber
Royal Berkshire NHS Foundation Trust>> NON - Formulary Item - contact pharmacy for advice
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Medicines that should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the primary care provider that the prescribing responsibility has been transferred. Where applicable, shared care protocols will be agreed and must be adhered to. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s)(DTC) and approved by Berkshire West APC.   

Brown

Drugs that have been reviewed and not recommended for prescribing. These drugs are not considered a cost effective use of scarce NHS resources. There may be individual patient specific or clinical reasons why a drug deemed low priority may be suitable for a particular patient. This is for the GP to condsider, weighing up the reasons against his/her allocated CCG budget. Where the decision is made to prescribe a low priority drug, detailed documentation must be included within the patients' notes for audit purposes. *Please note that low priority drug requests are unsuitable for the Case Review Committee and therefore should not be sent to this committee.   

Green

Medicines suitable for routine use and can be prescribed within primary care within their licensed indication in accordance with the BNF or other recognised national formulary. Primary care prescribers take full responsibility for prescribing  

Red

Medicines which should be prescribed by specialists only  

netFormulary